What are the first-line antihypertensive medications for an African-American adult with uncomplicated essential hypertension?

First-Line Antihypertensive Therapy for African Americans

For African American adults with uncomplicated essential hypertension, initiate treatment with either a thiazide-type diuretic (preferably chlorthalidone) or a calcium channel blocker (CCB) as first-line monotherapy, or use combination therapy with both agents if blood pressure is ≥20/10 mm Hg above target. 1

Preferred First-Line Agents

Thiazide-Type Diuretics

• Chlorthalidone is the preferred thiazide-type diuretic based on superior outcomes in head-to-head trials, particularly for preventing heart failure in African American patients 1
• In the ALLHAT trial (the largest comparative effectiveness study), chlorthalidone demonstrated better outcomes than ACE inhibitors and CCBs in African Americans, with significantly lower rates of heart failure and stroke 1, 2
• Thiazide diuretics remain the drugs of choice for initial therapy in both Black and non-Black hypertensive patients 2

Calcium Channel Blockers

• CCBs are equally effective as thiazide diuretics for most cardiovascular outcomes except heart failure, where diuretics show superiority 1
• CCBs are an excellent alternative when thiazide diuretics are not tolerated 1
• Recent evidence suggests CCB + ACE inhibitor combinations may be preferable to diuretic + ACE inhibitor combinations in African ancestry patients, with lower rates of hypokalemia and hyperglycemia 3

Agents to Avoid as Monotherapy

ACE Inhibitors and ARBs

• ACE inhibitors and ARBs are notably less effective as monotherapy in African American patients compared to thiazide diuretics and CCBs 1
• In ALLHAT, lisinopril was significantly less effective than chlorthalidone in Black patients for:
  • Blood pressure reduction (greater systolic BP decrease with chlorthalidone) 2
  • Stroke prevention (RR 1.40 in Blacks vs 1.00 in non-Blacks) 2
  • Heart failure prevention (RR 1.30 in Blacks) 2
  • Combined cardiovascular disease outcomes (RR 1.19 in Blacks) 2
• ARBs may be better tolerated than ACE inhibitors (less cough and angioedema) but offer no proven advantage over ACE inhibitors for stroke or CVD prevention in this population 1

Beta-Blockers

• Beta-blockers are less effective than CCBs and thiazide diuretics for blood pressure control and cardiovascular outcomes 1
• In systematic reviews, beta-blockers were 30% less effective than thiazide diuretics and 36% less effective than CCBs 1
• Should not be used as first-line therapy unless specific cardiac indications exist 1

When to Use Combination Therapy

Stage 2 Hypertension

• Initiate with two first-line agents (either as separate agents or fixed-dose combination) when blood pressure is >20/10 mm Hg above target 1
• This recommendation is particularly important for African American patients who often require multiple agents to achieve control 1, 4

Preferred Combinations

• Thiazide diuretic + CCB is recommended by both ACC/AHA and ESC/ESH guidelines 1
• CCB + ACE inhibitor or ARB is supported by recent evidence showing better metabolic profiles and potentially better cardiovascular outcomes 3
• Diuretic + ACE inhibitor or ARB is effective, though the CCB-based combination may be preferable based on 2022 meta-analysis data 3

Single-Pill Combinations

• Strongly favored to improve adherence 1
• Common pitfall: Some single-pill combinations contain suboptimal doses of the thiazide diuretic component 1

Stage 1 Hypertension Approach

• Monotherapy is reasonable for stage 1 hypertension (BP 130-139/80-89 mm Hg) with sequential addition of agents as needed 1
• Start with either chlorthalidone or a CCB 1
• Titrate dosage and add second agent if target not achieved 1

Critical Considerations

Why This Matters for African Americans

• African Americans develop hypertension earlier, have higher average blood pressures, and experience worse disease severity than other populations 4
• Rates of stroke, heart failure, and end-stage renal disease are substantially higher in African Americans with hypertension 4
• The differential response to antihypertensive classes is clinically significant and impacts outcomes 1, 2

Avoiding Common Pitfalls

• Do not use ACE inhibitor + ARB combinations - this is potentially harmful and not recommended 1
• Do not deny beta-blockers if specific indications exist (e.g., heart failure, post-MI, angina), but recognize they require combination with diuretics for optimal BP control in African Americans 4, 5
• Do not assume all diuretics are equal - chlorthalidone has superior outcome data compared to hydrochlorothiazide 1

Special Populations Within African Americans

• Diabetic nephropathy: ACE inhibitors have particular value and may protect against progression despite being less effective for BP control alone 5
• Heart failure: ACE inhibitors or ARBs combined with diuretics are indicated 5
• Chronic kidney disease: The AASK trial showed ramipril reduced progression better than amlodipine in African Americans 6

Treatment Algorithm

1. Assess BP stage and cardiovascular risk 1
2. Stage 1 (130-139/80-89 mm Hg): Start chlorthalidone or CCB monotherapy 1
3. Stage 2 (≥140/90 mm Hg) or ≥20/10 mm Hg above target: Start dual therapy with thiazide diuretic + CCB 1
4. If monotherapy inadequate: Add CCB to diuretic or vice versa 1
5. If dual therapy inadequate: Add ACE inhibitor or ARB to create triple therapy 1
6. Resistant hypertension: Add spironolactone or refer to specialist 1